Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed) | RFA AI 20 057

Opportunity Information: Apply for RFA AI 20 057

The National Institutes of Health (NIH) funding opportunity titled "Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-AI-20-057; CFDA 93.855) is a discretionary grant program designed to support research that clarifies what the tuberculosis granuloma does in real disease settings and how it influences patient outcomes. In pulmonary TB, the granuloma is the signature organized immune structure that forms in the lung around Mycobacterium tuberculosis. It is often described as both protective and problematic: it can help contain infection, but it can also create a niche where bacteria persist, evade immune killing, and respond unevenly to antibiotics. This opportunity aims to deepen the field's understanding of that balance by encouraging studies that define the granuloma's role in disease progression, persistence, and response to treatment, with the long-term purpose of enabling better therapeutic strategies.

At its core, the opportunity emphasizes fundamental and translational research that examines how granulomas form, function, and change over time, and how those changes relate to clinically meaningful outcomes such as bacterial clearance, sterilization, relapse risk, tissue damage, and treatment success or failure. By focusing on the granuloma as a key biological unit of TB pathogenesis, NIH is signaling that improvements in TB therapy may depend not only on discovering new drugs, but also on understanding the microenvironments where drugs and immune cells actually interact with the pathogen. Work supported under this announcement would be expected to generate a stronger mechanistic knowledge base that could guide the design of host-directed therapies, improved drug regimens, or interventions that better penetrate or modulate granulomatous lesions.

The funding mechanism is an R01 research project grant, which typically supports a defined, investigator-driven research plan of several years and is suited to labs or consortia that can take on substantial mechanistic questions. A key boundary is stated directly in the title: "Clinical Trial Not Allowed." That means the program is not intended to fund prospective clinical intervention studies where participants are assigned to receive specific treatments or prevention strategies to evaluate health outcomes. Applicants can still often use clinical samples, observational human data, ex vivo analyses, animal models, advanced imaging, and other approaches that do not meet NIH's definition of a clinical trial, but the research cannot be structured as an interventional clinical trial.

Eligibility is broad and includes many types of organizations, reflecting NIH's intent to draw from a wide research ecosystem. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions when specified); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; Indian/Native American tribal governments that are not federally recognized; and non-U.S. entities (foreign organizations). This wide eligibility encourages participation from institutions and communities with diverse perspectives, including those in TB-endemic regions outside the United States where granuloma biology and treatment outcomes may be studied in relevant epidemiologic contexts.

From an administrative standpoint, the opportunity was created on September 29, 2020, and the original closing date listed is February 22, 2021. The listing indicates a grant funding instrument type, a health-related funding activity category, and NIH as the sponsoring agency. The award ceiling and expected number of awards are not specified in the provided source information, which typically means applicants would need to consult the full NIH notice and related budget guidance for any limits, expectations, or institute-specific constraints.

In practical terms, this opportunity is aimed at projects that can connect lesion-level biology to outcome-level questions in TB. A competitive application would usually be expected to articulate why granulomas are the critical unit of study for the chosen question, how the proposed methods will capture relevant aspects of granuloma structure and function (for example, cellular composition, spatial organization, metabolic and immune microenvironments, bacterial physiology, or drug distribution), and how findings will advance TB treatment science. The overarching goal is not simply descriptive work, but the kind of mechanistic understanding that can realistically inform improved therapeutic approaches and ultimately better TB disease and treatment outcomes.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2020-09-29.
• Applicants must submit their applications by 2021-02-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AI 20 057

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: